Patents Assigned to SmithKline Beecham Corporation
  • Compounds, compositions, and methods
    Patent number: 7528137
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: May 5, 2009
    Assignees: Cytokinetics, Inc., SmithKline Beecham Corporation
    Inventors: Bainian Feng, Gustave Bergnes, David J. Morgans, Jr., Dashyant Dhanak, Steven David Knight, Michael Gerard Darcy
  • Tricyclic-nucleoside compounds for treating viral infections
    Patent number: 7524825
    Abstract: Disclosed are compounds represented by formulae I, II, and III, and the compositions and methods thereof for treating viral infections caused by a Flaviviridae family virus.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: April 28, 2009
    Assignee: SmithKline Beecham Corporation
    Inventor: Jesse Daniel Keicher
  • Chromosome-based platforms
    Patent number: 7521240
    Abstract: Artificial chromosomes, including ACes, that have been engineered to contain available sites for site-specific, recombination-directed integration of DNA of interest are provided. These artificial chromosomes permit tractable, efficient, rational engineering of the chromosome for a variety of applications.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: April 21, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Edward Perkins, Carl Perez, Michael Lindenbaum, Amy Greene, Josephine Leung, Elena Fleming, Sandra Stewart
  • Pharmaceutical aerosol formulation
    Patent number: 7521042
    Abstract: The present invention relates to novel pharmaceutical aerosol formulations comprising: (A) a therapeutic agent in the form of particles coated by at least one coating excipient and at least one surfactant, in suspension in (B) a liquefied propellant gas for the administration of therapeutic agents particularly by the pulmonary route and to process for preparing these formulations. It also relates to novel particles suitable for use in such formulations.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: April 21, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Pascal Cavaillon, Nathalie Llorca, Olivier Louis, Patrick Rosier
  • Member of the TNF Ligand Family
    Publication number: 20090098129
    Abstract: The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprising: i) a polypeptide having the amino acid sequence of figure (1); or ii) a variant of the polypeptide of i).
    Type: Application
    Filed: November 26, 2008
    Publication date: April 16, 2009
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Stuart Neville Farrow, Allard Kaptein, Jeremy David Alisdair Kitson, Alison Janet Winder
  • IL-8 Receptor Antagonists
    Publication number: 20090093451
    Abstract: This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Application
    Filed: April 20, 2007
    Publication date: April 9, 2009
    Applicant: Smithkline Beecham Corporation
    Inventor: Jakob Busch-Petersen
  • Nicotinamide derivatives useful as p38 inhibitors
    Patent number: 7514456
    Abstract: Compounds of formula (I): are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.
    Type: Grant
    Filed: August 7, 2006
    Date of Patent: April 7, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Nicola Mary Aston, Paul Bamborough, Ann Louise Walker
  • Pyrimidine compounds
    Patent number: 7514446
    Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: April 7, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Ronda Davis-Ward, Robert Anthony Mook, Jr., Michael J Neeb, James M Salovich
  • Process for preparing substituted benzimidazole compounds
    Patent number: 7514568
    Abstract: The invention relates to new methods of preparing substituted benzimidazole compounds, such as 2-bromo-5,6-dichlorobenzimidazole, which are useful in the preparation of compounds having antiviral activity.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: April 7, 2009
    Assignee: SmithKline Beecham Corporation
    Inventor: Stephen Freeman
  • Aniline derivatives as selective androgen receptor modulators
    Patent number: 7514470
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: April 7, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla, David John Cowan, Andrew Lamont Larkin, Istvan Kaldor, Eugene Lee Stewart
  • Heterocyclic compounds
    Patent number: 7507741
    Abstract: Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: March 24, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: George Stuart Cockerill, Karen Elizabeth Lackey
  • Anti-??humanized monoclonal antibodies
    Patent number: 7504102
    Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin ?v?3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of ?v?3-mediated disorders, such as restenosis, in human patients.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: March 17, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Zdenka L Jonak, Kyung O Johanson, Alexander Taylor
  • N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
    Patent number: 7504413
    Abstract: Provided herein are certain substituted N-phenethylbenzamide of formula V: that may be useful for treating certain cellular proliferation diseases and disorders by modulating the activity of CENP-E.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: March 17, 2009
    Assignees: Cytokinetics, Inc., SmithKline Beecham Corporation
    Inventors: Xiangping Qian, Gustave Bergnes, Dashyant Dhanak, Steven D. Knight, Nicholas D. Adams, Cynthia A. Parrish
  • Method of screening for inhibitors of osteopontin
    Patent number: 7504232
    Abstract: Amino acids (136 to 142) and amino acids (162 to 168) of human osteopontin constitute two sites at which osteopontin interacts with ?4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: March 17, 2009
    Assignee: Smithkline Beecham Corporation
    Inventors: Simon Barry, Carmel Horgan, Steven Ludbrook
  • CHEMICAL COMPOUNDS
    Publication number: 20090069302
    Abstract: The present invention relates generally to novel therapeutic compounds and AXOR 109 agonists, and processes for the manufacture and use of the same.
    Type: Application
    Filed: January 19, 2007
    Publication date: March 12, 2009
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Jerzy Ryszard Szewczyk, Christopher P. Laudeman, Thomas Dock, Zibin Chen, Anderson Evans, Yue H. Li
  • Chemical compounds
    Patent number: 7501512
    Abstract: This invention relates to newly identified inhibitors of kinases for treating various disorders.
    Type: Grant
    Filed: July 7, 2004
    Date of Patent: March 10, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Hideyuki Sato, Mio Takada, Yoshiaki Washio
  • AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS
    Publication number: 20090062307
    Abstract: The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.
    Type: Application
    Filed: October 31, 2008
    Publication date: March 5, 2009
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Michael John Alberti, David Harold Drewry, David Drysdale Miller, Paul Bamborough
  • Azaindole inhibitors of aurora kinases
    Patent number: 7495102
    Abstract: The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: February 24, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Martha A. Sarpong, Nicholas D. Adams, Jeffrey Michael Axten, Amita M. Chaudhari, Dashyant Dhanak, Toshihiro Hamajima, Kenneth Allen Newlander, Cynthia A. Parrish, Jerry Leroy Adams, Domingos J. Silva, Jun Tang
  • Crystal structure of liganded cFMS kinase domain
    Patent number: 7491731
    Abstract: A crystal structure of the cfms kinase domain, co-crystal structure with a bound small molecule, as well as methods of using the same in the discovery of cfms inhibitors and in the treatment of diseases mediated by inappropriate cfms activity.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: February 17, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Holly Kathleen Emerson, David Lee Musso, Stanley Dawes Chamberlain, Gregory Edward Peckham
  • Compounds, compositions and methods
    Patent number: 7491746
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: February 17, 2009
    Assignees: Cytokinetics, Inc., SmithKline Beecham Corporation
    Inventors: Andrew McDonald, Gustave Bergnes, Bainian Feng, David J. Morgans, Jr., Steven David Knight, Kenneth A. Newlander, Dashyant Dhanak, Christopher A. Brook